Alkermes (ALKS) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Powered by 
Analysis
Alkermes (ALKS) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.34 Bn | 625.58 Bn | 17.26 Bn | 2.47% |
| 2 | AbbVie | 441.84 Bn | 435.27 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 366.20 Bn | 359.06 Bn | 12.21 Bn | 39.28% |
| 4 | Novartis Ag | 266.65 Bn | 258.96 Bn | 11.24 Bn | 12.12% |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | -28.09% |
| 6 | Sanofi | 52.41 Bn | 45.03 Bn | 10.79 Bn | -36.57% |
| 7 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 8 | Incyte | 25.52 Bn | 20.98 Bn | 1.57 Bn | 42.23% |
| 9 | United Therapeutics | 21.51 Bn | 18.85 Bn | 683.80 Mn | 8.71% |
| 10 | Alkermes | 7.56 Bn | 6.91 Bn | 397.90 Mn | -86.97% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -86.97% |
| Mar 31, 2026 | -11.05% |
| Dec 31, 2025 | -17.42% |
| Sep 30, 2025 | 48.78% |
| Jun 30, 2025 | 69.74% |
| Mar 31, 2025 | 37.96% |
| Dec 31, 2024 | 5.40% |
| Sep 30, 2024 | 73.08% |
| Jun 30, 2024 | 237.28% |
| Mar 31, 2024 | 53.59% |
| Dec 31, 2023 | 68.77% |
| Sep 30, 2023 | 602.36% |
| Jun 30, 2023 | 115.83% |
| Mar 31, 2023 | -7.91% |
| Dec 31, 2022 | 66.97% |
| Sep 30, 2022 | -6.56% |
| Jun 30, 2022 | 10.47% |
| Mar 31, 2022 | 28.05% |
| Dec 31, 2021 | 89.27% |
| Sep 30, 2021 | 5.59% |